Study	Title	Journal	Sponsor/funding	Location(s)	Study design	Study arm(s)	Age (years)	Study period	n (model)	Relapses (%)
Hailu 2010	"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial"	PLoS Negl Trop Dis	DNDi/MSF	"5 centres: Ethiopia (Gondar University Hospital, Arba Minch Hospital); Sudan (MSF Treatment Centre, Um el Khjer; Ministry of Health Hospital, Kassab); Kenya (CCR, KEMRI, Nairobi)"	"Multicentre, open-label, randomised trial"	"(1) SSG, 20mg/kg, IV or IM, OD, 21D; (2) PM, 15mg/kg, IM, OD, 21D; (3) Combination of PM and SSG, same dose, frequency and route, 17D"	4--60	2004--2008	289	21 (7.3)
Khalil 2014	Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial 	PLoS Negl Trop Dis	DNDi (multiple funders)	"3 centres: Ethiopia (Gondar University Hospital, Arba Minch Hospital); Sudan (Ministry of Health Hospital, Kassab)"	"Multicentre, open-label, non-inferiority, randomised trial with adaptive design"	"LAMB, IV, either single dose at (1) 7.5mg/kg; (2) 10mg/kg; (3) 12.5mg/kg; (4) 15mg/kg, or multiple dose at (5) 3mg/kg, OD, D1-5, 14, 21 (total 21mg/kg)"	$\geq$4	2009--2011	92	11 (12.0)
Mbui 2019	"Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial"	Clin Infect Dis	DNDi (multiple funders)	"2 clinical sites: Kachelibra, West Pokot County, Kenya; Amudat, Karamoja sub-region, Uganda"	"Open-label, phase II, clinical trial"	"(1) MF, allometric dosing per sex, height, and weight, BD, PO, 28D\tnote{1}"	4--12	2015--2016	29	2 (6.9)
Musa 2010	"Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study"	PLoS Negl Trop Dis	DNDi (multiple funders)	"Ministry of Health Hospital, Kassab, Sudan"	"Open-label, open-label, phase II, randomised, dose-finding study"	"(1) PM, 15mg/kg, IM, OD, 28D; (2) PM, 20mg/kg, IM, OD, 21D"	4--60	2005--2006	40	8 (20.0)
Musa 2012	Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial	PLoS Negl Trop Dis	DNDi/MSF (multiple other funders)	"6 centres: 5 centres described in Khalil 2014 (above) and Amudat Hospital, Uganda. "	"Multicentre, open-label, parallel-arm, randomised trial"	"(1) SSG, 20mg/kg, IV or IM, OD, 30D; (2) PM, 20mg/kg, IM, OD, 21D; (3) combination of SSG, 20mg/kg, IV or IM, OD, 17D and PM, 15mg/kg, IM, OD, 17D "	4--60	2004--2010	638	30 (4.7%)
Ritmeijer 2001	Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome	Trans R Soc Trop Med Hyg	MSF	"Temporary MSF treatment centre, Densha, Ethiopia"	Open-label controlled trial with alterate allocation	"(1) SSG (generic), 20mg/kg, IM, 30D; (2) SSG (Pentostam, GlaxoWellcome), 20mg/kg, IM, 30D"	all	1998--1999	112	1 (0.9)
Ritmeijer 2006\tnote{MALE SEX}	A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection	Clin Infect Dis	MSF	"2 centres in Ethiopia: Humera Hospital, Mycadra Health Center"	"Open-label, randomised controlled trial"	"(1) SSG, 20mg/kg/day, IM, OD, 30D (extended if HIV positive); (2) MF, 100mg/day, PO, OD, 28D"	$\geq$15	2003--2005	248	6 (2.4)
Veeken 2000	A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan	Trop Med Int Health	MSF	"2 MSF treatment centres in Gedaref State, Sudan: Um Kuraa, Kassab "	"Open-label, randomised controlled trial"	"(1) SSG (generic), 20mg/kg, IM, 30D; (2) SSG (Pentostam, GlaxoWellcome), 20mg/kg, IM, 30D"	all	1998--1999	465	4 (0.9)
Wasunna 2016	Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. 	PLoS Negl Trop Dis	DNDi (multiple funders)	"3 centres: Kenya (Kimalel Health Centre); Sudan (Dooka Hospital and Ministry of Health Hospital, Kassab)"	"Phase II, open-label, non-comparative randomised trial (adaptive-sequential design)"	"(1) Combination of LAMB, 10mg/kg, IV, single dose, D1 and SSG, 20mg/kg, IM, OD, D2-11; (2) Combination of LAMB, 10mg/kg, IV, single dose, D1, and MF, 2.5mg/kg, PO, OD, D2-11; (3) MF, 2.5mg/kg, PO, OD, 28D"	7--60	2010--2012	138	16 (11.6)